--- title: "INKON Life announces its first cash dividend, distributing a cash dividend of 0.25 yuan for every 10 shares" type: "News" locale: "en" url: "https://longbridge.com/en/news/287783647.md" description: "INKON Life Technology Co., Ltd. announced the profit distribution plan for the year 2025, with the first cash dividend of RMB 0.25 per 10 shares and a capital reserve transfer of 3 shares. This dividend is based on 744,933,809 shares, totaling a cash dividend distribution of RMB 18,623,345.23, with cash dividends accounting for 27.17% of net profit. The company operates steadily, with a year-on-year revenue growth of 20.93% and a net profit growth of 28.50% in 2025" datetime: "2026-05-27T13:57:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287783647.md) - [en](https://longbridge.com/en/news/287783647.md) - [zh-HK](https://longbridge.com/zh-HK/news/287783647.md) generator: "portal-rs" --- # INKON Life announces its first cash dividend, distributing a cash dividend of 0.25 yuan for every 10 shares On May 27, 2026, INKON Life Science Technology Co., Ltd. (stock code: 300143) announced that the profit distribution plan for the year 2025 has entered the implementation stage. According to the announcement, the equity distribution plan is as follows: based on the existing total share capital of the company, after deducting the number of shares in the repurchase special securities account, which is 744,933,809 shares, a cash dividend of 0.25 yuan (including tax) will be distributed for every 10 shares to all shareholders, and at the same time, 3 additional shares will be allocated for every 10 shares from the capital reserve to all shareholders. The simultaneous implementation of cash dividends and capital reserve share increases marks the diversification of the company's shareholder return mechanism. **First Stock Dividend, Entering a New Stage of Shareholder Returns** According to the previously disclosed 2025 annual report, this profit distribution is based on the total share capital of the company as of December 31, 2025, which is 749,451,604 shares, minus the 4,517,795 shares in the repurchase special securities account, resulting in a base of 744,933,809 shares. A total cash dividend of 18,623,345.23 yuan (including tax) is proposed to be distributed, and after the increase, the total share capital of the company will rise to 972,931,746 shares. The cash dividend for this year accounts for 27.17% of the net profit attributable to shareholders of the listed company. In 2025, the company completed the use of capital reserves to offset losses and initiated its first dividend that year, reflecting the rapid transmission of improved operational fundamentals to shareholder value returns. The company stated on the investor interaction platform: "The simultaneous implementation of cash dividends and capital reserve share increases is based on the company's actual operating conditions and financial status, in conjunction with relevant laws and regulations and the provisions of the Articles of Association, aiming to balance reasonable returns for shareholders with the long-term development needs of the company." **Steady Operations Strengthen Dividend Foundation** The realization of the first dividend is rooted in the continuous improvement of the company's operational fundamentals. In 2025, the company achieved operating revenue of 1,885.5667 million yuan, a year-on-year increase of 20.93%; the net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 107.1323 million yuan, a year-on-year increase of 28.50%; the net cash flow from operating activities was 340.8316 million yuan, a year-on-year increase of 31.47%. The company achieved dual improvements in revenue scale and profitability, further optimizing cash flow and providing a solid foundation for shareholder returns. Entering 2026, the company continues its steady growth trend. In the first quarter, it achieved operating revenue of 496 million yuan, a year-on-year increase of 21.36%; net profit was 30.51 million yuan, a year-on-year increase of 4.90%; and operating cash flow was 87.22 million yuan, a year-on-year increase of 26.99%. The number of users in self-operated hospitals increased by 15% year-on-year, with outpatient visits increasing by 14% year-on-year and inpatient visits increasing by 30%, continuously expanding the scale of patient services. While the quality of operations steadily improves, the company's strategic transformation is also ongoing. In 2025, the company began its transition from a comprehensive medical group driven by both medical services and medical devices to an AI-enabled proactive health ecosystem platform. The tumor full-cycle health management app "Smart Care INKON" was launched, and the layout of brain science is steadily advancing, with its Sichuan Friendship Hospital and Qingdao Yinghai Hospital selected for the national cooperative medical institution list for Parkinson's disease SCAN loop stimulation treatment From resolving historical losses to the first dividend payout, from governance recognition to strategic upgrades, the company is gradually fulfilling its commitment to "high-quality development." Looking ahead, INKON Life will continue to deepen the synergistic resonance of medical innovation, green transformation, and social welfare, creating long-term value for shareholders through continuously improving operational quality and increasingly refined corporate governance ### Related Stocks - [300143.CN](https://longbridge.com/en/quote/300143.CN.md) ## Related News & Research - [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md) - [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md) - [The Platform Group: Acquired Cocoli.com to strengthen the furniture marketplace, with EUR 728M revenue in 2025](https://longbridge.com/en/news/296441852.md) - [08:08 ETSitero Extends Ash, a Clinical AI Agent, Across the Full Clinical Data Lifecycle](https://longbridge.com/en/news/296226254.md) - [Genetix kicks off sickle cell disease awareness campaign](https://longbridge.com/en/news/296468544.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**